Loading...

David Siegel, PhD

TitlePostdoctoral Scholar
SchoolUCSF School of Medicine
DepartmentMedicine
Address1550 4th Street, Bldg 19B
San Francisco CA 94158
Phone415-502-2027
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, BerkeleyPhD2012Physics
    Cornell UniversityBA2005Physics and Mathematics

    Collapse Overview 
    Collapse Overview
    David Siegel is a statistical genetics postdoc in the Noah Zaitlen group at UCSF.


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sanchez L, Vesole DH, Richter JR, Biran N, Bilotti E, McBride L, Anand P, Ivanovski K, Siegel D. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Br J Haematol. 2016 Nov 18. PMID: 27859001.
      View in: PubMed
    2. Biran N, Rowley SD, Vesole DH, Zhang S, Donato ML, Richter J, Skarbnik AP, Pecora A, Siegel D. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2016 Dec; 22(12):2165-2171. PMID: 27590107.
      View in: PubMed
    3. Bilotti E, Vesole DH, McBride L, Schmidt L, Gao Z, Gilani M, McNeill A, Bednarz U, Richter J, Mato A, Graef T, Siegel D. Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2016 Oct; 16(10):558-562. PMID: 27769558.
      View in: PubMed
    4. Bloudek L, Roy A, Kish JK, Siegel D, Jagannath S, Globe D, Orloski L, Kuriakose ET. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model. J Manag Care Spec Pharm. 2016 Aug; 22(8):991-1002. PMID: 27459662.
      View in: PubMed
    5. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špicka I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1; 128(9):1174-80. PMID: 27439911.
      View in: PubMed
    6. Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol. 2016 Jul; 9(7):707-17. PMID: 27291638.
      View in: PubMed
    7. Siegel D, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, Song KW, San Miguel JF, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma. 2016 Dec; 57(12):2833-2838. PMID: 27267105.
      View in: PubMed
    8. Ghobrial IM, Siegel D, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Am J Hematol. 2016 Jun; 91(4):400-5. PMID: 26800393.
      View in: PubMed
    9. Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. Br J Haematol. 2016 Jun; 173(6):884-95. PMID: 27071340.
      View in: PubMed
    10. Siegel D, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2016 Jun; 16(6):329-334.e1. PMID: 27025160.
      View in: PubMed
    11. Jurczyszyn A, Olszewska-Szopa M, Vesole AS, Vesole DH, Siegel D, Richardson PG, Paba-Prada C, Callander NS, Huras H, Skotnicki AB. Multiple Myeloma in Pregnancy-A Review of the Literature and a Case Series. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):e39-45. PMID: 26847816.
      View in: PubMed
    12. Squifflet P, Michiels S, Siegel D, Vij R, Jagannath S, Saad ED, Rajangam K, Ro SK, Buyse M. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):680-6. PMID: 26482107.
      View in: PubMed
    13. DA Siegel, F El Gabaly, KF McCarty, NC Bartelt. In situ characterization of the formation of a mixed conducting phase on the surface of yttria-stabilized zirconia near Pt electrodes. Physical Review B. 2015; 92(12):125421.
      View Publication
    14. Roy A, Kish JK, Bloudek L, Siegel D, Jagannath S, Globe D, Kuriakose ET, Migliaccio-Walle K. Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework. Am Health Drug Benefits. 2015 Jun; 8(4):204-15. PMID: 26157542; PMCID: PMC4489189.
      View in: PubMed, PubMed Central
    15. Vesole DH, Bilotti E, Richter JR, McNeill A, McBride L, Raucci L, Anand P, Bednarz U, Ivanovski K, Smith J, Batra V, Aleman A, Sims T, Guerrero L, Mato A, Siegel D. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2015 Oct; 171(1):52-9. PMID: 26018491.
      View in: PubMed
    16. Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel D. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015 Oct; 56(10):2959-61. PMID: 25699653.
      View in: PubMed
    17. Vesole DH, Siegel D. Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trials. Clin Adv Hematol Oncol. 2015 Mar; 13(3):163, 167-9. PMID: 26352424.
      View in: PubMed
    18. Vesole DH, Siegel D. Pretransplant induction regimens for multiple myeloma. Biol Blood Marrow Transplant. 2015 Feb; 21(2):200-1. PMID: 25534538.
      View in: PubMed
    19. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8; 372(2):142-52. PMID: 25482145.
      View in: PubMed
    20. Liu L, Siegel D, Chen W, Liu P, Guo J, Duscher G, Zhao C, Wang H, Wang W, Bai X, McCarty KF, Zhang Z, Gu G. Unusual role of epilayer-substrate interactions in determining orientational relations in van der Waals epitaxy. Proc Natl Acad Sci U S A. 2014 Nov 25; 111(47):16670-5. PMID: 25385622; PMCID: PMC4250159.
      View in: PubMed, PubMed Central
    21. Choongyu Hwang, Duck Young Kim, David A Siegel, Kevin T Chan, Jesse Noffsinger, Alexei V Fedorov, Marvin L Cohen, Börje Johansson, Jeffrey B Neaton, Alessandra Lanzara. Ytterbium-driven strong enhancement of electron-phonon coupling in graphene. Physical Review B. 2014; 90(11):115417.
      View Publication
    22. Papadopoulos KP, Siegel D, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015 Mar 1; 33(7):732-9. PMID: 25225420.
      View in: PubMed
    23. Kevin F McCarty, Matteo Monti, Shu Nie, David A Siegel, Elena Starodub, Farid El Gabaly, Anthony H McDaniel, Andrey Shavorskiy, Tolek Tyliszczak, Hendrik Bluhm, Norman C Bartelt, Juan de la Figuera. Oxidation of magnetite (100) to hematite observed by in situ spectroscopy and microscopy. The Journal of Physical Chemistry C. 2014; 118(34):19768-19777.
      View Publication
    24. Siegel D. Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000. Haematologica. 2014 Aug; 99(8):e147. PMID: 25082788; PMCID: PMC4116849.
      View in: PubMed, PubMed Central
    25. Donato ML, Siegel D, Vesole DH, McKiernan P, Nyirenda T, Pecora AL, Baker M, Goldberg SL, Mato A, Goy A, Rowley SD. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1211-6. PMID: 24792872.
      View in: PubMed
    26. Richardson PG, Siegel D, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32. PMID: 24421329; PMCID: PMC3962162.
      View in: PubMed, PubMed Central
    27. Liu L, Park J, Siegel D, McCarty KF, Clark KW, Deng W, Basile L, Idrobo JC, Li AP, Gu G. Heteroepitaxial growth of two-dimensional hexagonal boron nitride templated by graphene edges. Science. 2014 Jan 10; 343(6167):163-7. PMID: 24408431.
      View in: PubMed
    28. Siegel D. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib. Oncology (Williston Park). 2013 Dec; 27 Suppl 3:2-3. PMID: 25184229.
      View in: PubMed
    29. Siegel D. From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol. 2013 Dec; 4(6):354-65. PMID: 24319571; PMCID: PMC3854560.
      View in: PubMed, PubMed Central
    30. Wang TP, Safran SG, Richter JR, Siegel D, Vesole DH. Subepithelial corneal immunoglobulin deposition as a manifestation of multiple myeloma: a case report and literature review. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e39-42. PMID: 24211225.
      View in: PubMed
    31. Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013 Nov; 163(4):478-86. PMID: 24112026.
      View in: PubMed
    32. Siegel D, Chueh WC, El Gabaly F, McCarty KF, de la Figuera J, Blanco-Rey M. Determination of the surface structure of CeO2(111) by low-energy electron diffraction. J Chem Phys. 2013 Sep 21; 139(11):114703. PMID: 24070301.
      View in: PubMed
    33. Dimopoulos M, Siegel D, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct; 14(11):1129-40. PMID: 24055414.
      View in: PubMed
    34. San-Miguel JF, Richardson PG, Günther A, Sezer O, Siegel D, Bladé J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Mu S, Bourquelot PM, Victoria Mateos M, Anderson KC. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013 Oct 10; 31(29):3696-703. PMID: 24019544.
      View in: PubMed
    35. Wang M, Martin T, Bensinger W, Alsina M, Siegel D, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31; 122(18):3122-8. PMID: 24014245; PMCID: PMC3814729.
      View in: PubMed, PubMed Central
    36. Cohen-Wolkowiez M, Sampson M, Bloom BT, Arrieta A, Wynn JL, Martz K, Harper B, Kearns GL, Capparelli EV, Siegel D, Benjamin DK, Smith PB. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J. 2013 Sep; 32(9):956-61. PMID: 23587979; PMCID: PMC3769518.
      View in: PubMed, PubMed Central
    37. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013 Nov; 98(11):1753-61. PMID: 23935022; PMCID: PMC3815177.
      View in: PubMed, PubMed Central
    38. Nie S, Starodub E, Monti M, Siegel D, Vergara L, El Gabaly F, Bartelt NC, de la Figuera J, McCarty KF. Insight into magnetite's redox catalysis from observing surface morphology during oxidation. J Am Chem Soc. 2013 Jul 10; 135(27):10091-8. PMID: 23763580.
      View in: PubMed
    39. Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, Dimopoulos M. The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2014 Jan; 55(1):11-8. PMID: 23614765.
      View in: PubMed
    40. Siegel D, Regan W, Fedorov AV, Zettl A, Lanzara A. Charge-carrier screening in single-layer graphene. Phys Rev Lett. 2013 Apr 5; 110(14):146802. PMID: 25167021.
      View in: PubMed
    41. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel D, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56. PMID: 23447001; PMCID: PMC4149337.
      View in: PubMed, PubMed Central
    42. Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7. PMID: 23243282; PMCID: PMC4123324.
      View in: PubMed, PubMed Central
    43. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel D. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):310-8. PMID: 23040437.
      View in: PubMed
    44. David A Siegel, Choongyu Hwang, Alexei V Fedorov, Alessandra Lanzara. Electron–phonon coupling and intrinsic bandgap in highly-screened graphene. New Journal of Physics. 2012; 14(9):095006.
      View Publication
    45. Choongyu Hwang, David A Siegel, Sung-Kwan Mo, William Regan, Ariel Ismach, Yuegang Zhang, Alex Zettl, Alessandra Lanzara. Fermi velocity engineering in graphene by substrate modification. Scientific reports. 2012; 2:590.
      View Publication
    46. Vij R, Siegel D, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48. PMID: 22845873.
      View in: PubMed
    47. Siegel D, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4; 120(14):2817-25. PMID: 22833546; PMCID: PMC4123387.
      View in: PubMed, PubMed Central
    48. Siegel D. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance. Semin Hematol. 2012 Jul; 49 Suppl 1:S3-15. PMID: 22727390.
      View in: PubMed
    49. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel D. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70. PMID: 22555973; PMCID: PMC4123327.
      View in: PubMed, PubMed Central
    50. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Sep; 53(9):1820-3. PMID: 22288662.
      View in: PubMed
    51. Tufail M, Siegel D, McBride L, Bilotti E, Bello E, Anand P, Olivo K, Bendarz U, McNeill A, Vesole DH. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):186-90. PMID: 22381702.
      View in: PubMed
    52. Mato A, Feldman T, Richter J, Siegel D, Goy A. Liquid tumors in the elderly. Clin Geriatr Med. 2012 Feb; 28(1):115-52. PMID: 22326039.
      View in: PubMed
    53. Jakubowiak AJ, Benson DM, Bensinger W, Siegel D, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012 Jun 1; 30(16):1960-5. PMID: 22291084.
      View in: PubMed
    54. Choongyu Hwang, Cheol-Hwan Park, David A Siegel, Alexei V Fedorov, Steven G Louie, Alessandra Lanzara. Direct measurement of quantum phases in graphene via photoemission spectroscopy. Physical Review B. 2011; 84(12):125422.
      View Publication
    55. Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel D, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011 Nov; 155(3):340-8. PMID: 21902684; PMCID: PMC3192237.
      View in: PubMed, PubMed Central
    56. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel D, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011 Oct 20; 118(16):4359-62. PMID: 21860025; PMCID: PMC3204907.
      View in: PubMed, PubMed Central
    57. Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C, Goddard J, Dunbar J, Normant E, Adams J, Grayzel D, Anderson KC, Richardson P. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2011 Dec; 52(12):2308-15. PMID: 21851215.
      View in: PubMed
    58. Siegel D, Park CH, Hwang C, Deslippe J, Fedorov AV, Louie SG, Lanzara A. Many-body interactions in quasi-freestanding graphene. Proc Natl Acad Sci U S A. 2011 Jul 12; 108(28):11365-9. PMID: 21709258; PMCID: PMC3136305.
      View in: PubMed, PubMed Central
    59. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7. PMID: 21477075.
      View in: PubMed
    60. Siegel D, Vij R, Jakubowiak AJ. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma. Clin Adv Hematol Oncol. 2011 Apr; 9(4):1-15. PMID: 21928467.
      View in: PubMed
    61. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel D, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72. PMID: 21430775; PMCID: PMC3560292.
      View in: PubMed, PubMed Central
    62. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 5; 117(18):4691-5. PMID: 21292775; PMCID: PMC3710442.
      View in: PubMed, PubMed Central
    63. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):38-43. PMID: 21273172.
      View in: PubMed
    64. David A Siegel, CG Hwang, Alexei V Fedorov, Alessandra Lanzara. Quasifreestanding multilayer graphene films on the carbon face of SiC. Physical Review B. 2010; 81(24):241417.
      View Publication
    65. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010 Jun 20; 28(18):3015-22. PMID: 20479412.
      View in: PubMed
    66. SD Lounis, DA Siegel, R Broesler, CG Hwang, EE Haller, A Lanzara. Resonant photoluminescent charging of epitaxial graphene. Applied Physics Letters. 2010; 96(15):151913.
      View Publication
    67. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel D, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4. PMID: 20118399; PMCID: PMC2813833.
      View in: PubMed, PubMed Central
    68. David A Siegel, SY Zhou, F El Gabaly, Andreas K Schmid, Kevin F McCarty, Alessandra Lanzara. Three-fold diffraction symmetry in epitaxial graphene and the SiC substrate. Physical Review B. 2009; 80(24):241407.
      View Publication
    69. Sprinkle M, Siegel D, Hu Y, Hicks J, Tejeda A, Taleb-Ibrahimi A, Le Fèvre P, Bertran F, Vizzini S, Enriquez H, Chiang S, Soukiassian P, Berger C, de Heer WA, Lanzara A, Conrad EH. First direct observation of a nearly ideal graphene band structure. Phys Rev Lett. 2009 Nov 27; 103(22):226803. PMID: 20366119.
      View in: PubMed
    70. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel D, Katz M, Greipp PR. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan; 11(1):29-37. PMID: 19853510; PMCID: PMC3042271.
      View in: PubMed, PubMed Central
    71. SY Zhou, ÇÖ Girit, A Scholl, CJ Jozwiak, DA Siegel, P Yu, JT Robinson, F Wang, A Zettl, A Lanzara. Instability of two-dimensional graphene: Breaking s p 2 bonds with soft x rays. Physical Review B. 2009; 80(12):121409.
      View Publication
    72. Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, Kumar S, Bahlis NJ, Alsina M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009 Jul; 146(2):164-70. PMID: 19545290; PMCID: PMC2728892.
      View in: PubMed, PubMed Central
    73. Hyunyong Choi, Ferenc Borondics, David A Siegel, Shuyun Y Zhou, Michael C Martin, Alessandra Lanzara, Robert A Kaindl. Broadband electromagnetic response and ultrafast dynamics of few-layer epitaxial graphene. Applied Physics Letters. 2009; 94(17):172102.
      View Publication
    74. David A Siegel, Shuyun Y Zhou, Farid El Gabaly, Alexei V Fedorov, Andreas K Schmid, Alessandra Lanzara. Self-doping effects in epitaxially grown graphene. Applied Physics Letters. 2008; 93(24):243119.
      View Publication
    75. SY Zhou, DA Siegel, AV Fedorov, A Lanzara. Kohn anomaly and interplay of electron-electron and electron-phonon interactions in epitaxial graphene. Physical Review B. 2008; 78(19):193404.
      View Publication
    76. Jagannath S, Barlogie B, Berenson JR, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov; 143(4):537-40. PMID: 18783399.
      View in: PubMed
    77. Zhou SY, Siegel D, Fedorov AV, Lanzara A. Metal to insulator transition in epitaxial graphene induced by molecular doping. Phys Rev Lett. 2008 Aug 22; 101(8):086402. PMID: 18764644.
      View in: PubMed
    78. SY Zhou, DA Siegel, AV Fedorov, A Lanzara. Departure from the conical dispersion in epitaxial graphene. Physica E: Low-dimensional Systems and Nanostructures. 2008; 40(7):2642-2647.
      View Publication
    79. SY Zhou, DA Siegel, AV Fedorov, F El Gabaly, AK Schmid, AH Castro Neto, D-H Lee, A Lanzara. Origin of the energy bandgap in epitaxial graphene. Nature Materials. 2008; 7(4):259-260.
      View Publication
    80. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008 Mar; 49(3):502-7. PMID: 18297527.
      View in: PubMed
    81. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22; 357(21):2133-42. PMID: 18032763.
      View in: PubMed
    82. Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PMID: 18000495.
      View in: PubMed
    83. Berenson JR, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Talisman Pomeroy J, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong SF, Moss R, Patel R, Ferretti D, Russell K, Louie R, Yeh HS, Swift RA. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol. 2006 Oct; 135(2):174-83. PMID: 17010047.
      View in: PubMed
    84. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006 Oct; 135(2):158-64. PMID: 16939489.
      View in: PubMed
    85. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel D, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 1; 24(19):3113-20. PMID: 16754936.
      View in: PubMed
    86. Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol. 2003 Nov; 123(3):484-9. PMID: 14617011.
      View in: PubMed
    87. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26; 348(26):2609-17. PMID: 12826635.
      View in: PubMed
    88. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003 May 15; 101(10):3849-56. PMID: 12531801.
      View in: PubMed
    89. Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002 Apr; 117(1):103-8. PMID: 11918539.
      View in: PubMed
    90. Niesvizkya R, Choy CG, Siegel D, Lyons L, Michaeli J. Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrate. Leuk Lymphoma. 2002 Mar; 43(3):603-5. PMID: 12002765.
      View in: PubMed
    91. Niesvizky R, Siegel D, Glassman J, Straus D, Fine J, Lyons L, Michaeli J. Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features. Leuk Lymphoma. 2002 Mar; 43(3):607-12. PMID: 12002766.
      View in: PubMed
    David's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (193) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (2) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    Back to TOP